Novaremed AG: Novaremed's Non-opioid Lead Compound, NRD.E1, to be Tested in NIH HEAL Initiative Phase 2 Trial for the Treatment of Chronic Pain
NIH, through the Helping to End Addiction Long-term Initiative, to sponsor the Phase 2b SERENDIPITY-1 study, evaluating NRD.E1 in patients with painful diabetic peripheral neuropathy (PDPN)
United States Mark Altmeyer Kostenloser Wertpapierhandel Eva Tiecke Isaac Kobrin Early Phase Pain Investigation Clinical Network
Source: finanznachrichten.de